Lecia Bushak explains this week’s FDA advisory committee hearing on whether to withdraw Covis Pharma’s preterm birth drug Makena from the market, and what the case means for the agency’s larger accelerated approval pathway. She also speaks with a few of the winners at this month’s MM+M Awards ceremony.